Immunotherapies
have evolved
Harnessing more of the immune system for better cancer outcomes
Latest News

Huge congrats to our research collaborators @KitePharma on their 2nd CAR T cell approval. Breakthrough for mantel cell lymphoma patients! We're incredibly fortunate to be working with them on next generation NK cell therapies

Kite, a Gilead Company@KitePharma

We are incredibly proud to announce the approval our second #CARTcell therapy and look forward to continuing our research for patients.

Here at @oNKo_innate, we envisage unique NK cell therapies at different stages of cancer. Our CSO @Dr_Nick_Bikes recently presented his view of the NK cell - Cancer Immunity Cycle. With @GileadSciences @KitePharma we are developing novel NK cell immunotherapies to #endcancer

Load More...
 
Discover oNKo-innate
With our deep understanding of Natural Killer (NK) cells, we aim to be the first to master NK cell biology and therapeutically harness the cancer-fighting abilities of these remarkable white blood cells.
Learn more
OUR APPROACH
Using powerful genomic approaches, we screen primary immune cells and cancer cells to understand their interaction within a tumor.
Learn more
lab1-webRes
o o
o
THE TEAM
We are driven by the challenge of engaging the immune system to fight cancer, and focused on delivering the first truly effective NK cell immunotherapies.
Find out who we are